SecBot SecBot
144 ·Filed Jun 24, 2026

HRMY

Harmony Biosciences Holdings, Inc.
BEARISH
Impact 5/10
Horizondays Processed4mo ago SEC0001950047-26-006445
Form 144, notice of proposed sale of securities
Actionable Insight ▼ Bearish

Monitor for additional Form 144 or Form 4 filings from Kapadia and other insiders. The sustained selling pattern by a former officer over the past six weeks is a negative signal. Watch next earnings for any fundamental deterioration that might explain the insider reduction.

DirectionBearish
Confidencemedium
Horizondays

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$34.13
T+0 close · Jun 24, 2026 · via day close
Latest settled
+4.89%
T+20 · $35.80
Vs SPY
+4.36%
α at T+20
Next horizon
T+60
due 8w ago
  1. T+0 · Jun 25 $34.13entry
  2. T+1 · 5mo ago +3.93%α +4.65% · $35.47
  3. T+5 · 5mo ago +5.48%α +3.92% · $36.00
  4. T+20 · 4mo ago +4.89%α +4.36% · $35.80
  5. T+60 · due 8w ago Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Former officer Sandip Kapadia filed a Form 144 notice of intent to sell 4,406 shares of Harmony Biosciences common stock, valued at approximately $154,302, via Morgan Stanley. The shares were acquired through option exercises under a registered plan. Kapadia has sold a total of 82,606 shares since early May 2026, representing a meaningful reduction of his position.

Key Facts

  • Former officer Sandip Kapadia filed Form 144 on 2026-06-24 to sell 4,406 shares (~$154,302).
  • Shares were acquired via exercise of options under a registered plan on the same date.
  • Kapadia has sold 82,606 shares total since May 8, 2026, including 27,960 on 6/9, 2,101 on 6/5, 7,064 on 6/4, and 45,481 on 5/8.
  • The filing does not disclose Kapadia's remaining holdings, but the cumulative sales since May 8 represent a significant insider reduction.
  • The stock trades on Nasdaq under ticker HRMY with a $2.0B market cap.

Financial Impact

Proposed sale of 4,406 shares at ~$154,302; cumulative insider sales of 82,606 shares since May 8, 2026.

insider holdingsdilution

Risk Factors

  • Insider selling may indicate lack of confidence in near-term prospects or upcoming negative catalyst.
  • Further insider sales could pressure the stock price.
  • The selling is by a former officer, which may be part of routine post-employment diversification, but the volume and timing are notable.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
65% bullish (17 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-006445
Document: 0001950047-26-006445-index.html0001950047-26-006445
Document: 0001950047-26-006445.txt0001950047-26-006445

US Market Status

Market Closed · Opens in 7h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 24, 2026